Cardiovascular disease (CVD) is the main cause of morbidity and mortality in dialysis patients. The occurrence rate of CVD is 30 times higher in End-Stage Renal Disease (ESRD) patients than in the general population. While the impairment of the renal function is, in itself, sufficient to cause cardiovascular disorders, several additional risk factors attributable to ESRD have been identified, such as fluid overload, anaemia, electrolyte disorders, chronic inflammation, etc.
Several cardiovascular risk factors can be minimized with proper dialysis therapies
Preventing CVD is the primary object when treating patients with Chronic Kidney Disease (CKD). Hospal provides a full range of advanced therapies aimed at improving the well being of haemodialysis patients and at limiting associated cardiovascular risk factors.
The biofeedback systems (Hemocontrol and Diacontrol) offered by Hospal, Physio dialysis, may have a beneficial effect on overall cardiovascular risk by preventing intra-dialysis hypotension as well as managing volume expansion and/or plasma sodium to reduce hypertension.
Due to the absence of acetate and the use of AN69ST, the most biocompatible membrane, AFB™ therapies can also limit cardiovascular risk factors.